Paris Brain Institute

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Paris Brain Institute (ICM)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Paris, France (Pitié-Salpêtrière Hospital)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Translational Research Center</td>
</tr>
<tr>
<td class="label">Established</td>
<td>2010</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://icm-institute.org" target="_blank">https://icm-institute.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Huntington's Disease](/diseases/huntingtons)</td>
</tr>
<tr>
<td class="label">Research Groups</td>
<td>50+ research teams</td>
</tr>
</table>

Paris Brain Institute (Institut du Cerveau et de la Moelle épinière)

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Paris Brain Institute (ICM)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Paris, France (Pitié-Salpêtrière Hospital)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Translational Research Center</td>
</tr>
<tr>
<td class="label">Established</td>
<td>2010</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://icm-institute.org" target="_blank">https://icm-institute.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Huntington's Disease](/diseases/huntingtons)</td>
</tr>
<tr>
<td class="label">Research Groups</td>
<td>50+ research teams</td>
</tr>
</table>

Paris Brain Institute (Institut du Cerveau et de la Moelle épinière)

Overview

The Paris Brain Institute (Institut du Cerveau et de la Moelle épinière, ICM) is a world-leading translational research center dedicated to neurological and psychiatric diseases. Located at the Pitié-Salpêtrière Hospital in Paris, one of Europe's largest teaching hospitals, the institute brings together clinicians, researchers, and patients in a unique collaborative environment dedicated to understanding and treating diseases of the brain and spinal cord["@paris2026"].

Founded in 2010 as a major initiative in French neuroscience research, the ICM represents one of the most ambitious neuroscience projects in Europe. The institute was established with support from the French government, the Assistance Publique-Hôpitaux de Paris (AP-HP), and leading research organizations["@aphp2026"]. Its mission is to accelerate the translation of basic neuroscience discoveries into clinical applications for patients with neurodegenerative and neurological disorders.

History and Institutional Background

Foundation and Evolution

The Paris Brain Institute emerged from a strategic recognition that major advances in neuroscience required unprecedented collaboration between basic researchers and clinicians. The institute was established in 2010 on the historic site of Pitié-Salpêtrière Hospital, which has been a center of neurological excellence since the 19th century when Jean-Martin Charcot pioneered the study of neurological diseases.

Since its founding, the ICM has grown from an initial cohort of 20 research teams to over 50 teams, with more than 600 researchers and clinicians working across the full spectrum of neuroscience research. The institute has invested heavily in state-of-the-art infrastructure, including advanced neuroimaging facilities, genomics platforms, and clinical research units.

Key Milestones

• 2010: Institute founded with 20 initial research teams
• 2013: Opening of the Human Brain Bank with over 500 specimens
• 2015: Launch of the iPSC generation facility
• 2017: Installation of 7T MRI scanner for research
• 2019: Single-cell genomics platform established
• 2022: Expansion of clinical trials unit

Research Mission

The institute's primary mission is to understand the nervous system and develop new treatments for brain and spinal cord diseases through:

• Fundamental research: Molecular, cellular, and systems neuroscience
• Clinical research: Translational studies and clinical trials
• Therapeutic innovation: Drug development and gene therapy approaches
• Data science: Bioinformatics and AI for neuroscience

Major Research Programs

Neurodegenerative Diseases Program

The ICM hosts one of Europe's largest programs in neurodegenerative disease research, with particular focus on:

Alzheimer's Disease and Related Dementias

Research on [Alzheimer's Disease](/diseases/alzheimers-disease) encompasses:

• Biomarker development: CSF and blood-based biomarkers for early diagnosis[@pasquier2023]
• Early-onset AD: Characterization of atypical presentations[@duron2021]
• Genetics: APP, [PSEN1](/genes/psen1), and [PSEN2](/genes/psen2) mutations in French families[@hannequin2020]
• Tau imaging: PET imaging of tau pathology in French cohorts[@lebersidan2023]
• Clinical trials: Phase I-III trials for disease-modifying therapies

Parkinson's Disease and Movement Disorders

The ICM is a global leader in [Parkinson's Disease](/diseases/parkinsons-disease) research:

• Genetics: Extensive work on [LRRK2](/genes/lrrk2), [GBA](/genes/gba), and [SNCA](/genes/snca) variants in French populations[@corvol2018][@lesage2016]
• Alpha-synuclein biology: Seed amplification assays and prion-like propagation studies[@delamarre2021]
• Deep brain stimulation: Pioneering work on DBS for PD[@vidailhet2018][@duret2019]
• Neuroinflammation: Studies on microglial activation and cytokine profiles[@simonnet2022]
• Biomarkers: Development of multimodal biomarker panels[@bertran2021]

Amyotrophic Lateral Sclerosis (ALS)

The ICM hosts a comprehensive ALS research program:

• Genetics: French ALS genetics registry and C9orf72 studies[@rouviere2022][@blasco2021]
• SOD1 research: Characterization of SOD1 mutations in French families[@gougeon2020]
• Clinical trials: Multiple Phase I-III trials for novel therapies

Huntington's Disease

Research on [Huntington's Disease](/diseases/huntingtons-disease) includes:

• HTT biology: Understanding mutant huntingtin toxicity
• Therapeutic development: HTT lowering approaches[@monet2021]

Technology Platforms

The ICM maintains state-of-the-art research facilities:

Human Brain Bank

• Over 1,000 post-mortem brain specimens
• Rapid autopsy program (within 24 hours)
• Specialized collections for AD, PD, ALS, MS

iPSC Facility

• Generation of patient-derived iPSCs
• Differentiation to neurons, astrocytes, microglia

Neuroimaging Suite

• 7T MRI scanner (one of few in Europe)
• PET/CT scanner

Notable Researchers

• Prof. Alexis Brice - Former Director, Parkinson's disease genetics pioneer[@brice2019]
• Prof. Bertrand Fontaine - ALS and neuromuscular disorders
• Prof. Marie Vidailhet - Movement disorders and deep brain stimulation[@vidailhet2018]

International Collaborations

The ICM maintains active partnerships with:

• European Alzheimer's Disease Consortium
• International Parkinson's Disease Genomics Consortium (IPDGC)
• ALS Genetics Consortium
• National Institutes of Health (USA)

Future Directions

Strategic Priorities

External Links

• [Paris Brain Institute Official](https://icm-institute.org)
• [AP-HP Research](https://recherche.ap-hp.fr)

See Also

• [French Neuroscience Institutions](/institutions)
• [Alzheimer's Disease Research Centers](/institutions/alzheimers-disease-research-centers)
• [Parkinson's Disease Research Centers](/institutions)

References